New Licenses. Purchasers and New Operators shall have received adequate assurance of obtaining all governmental and quasi-governmental licenses and other regulatory approvals needed to own and operate the Facilities under Kansas law (e.g. a comfort letter from KDADS stating that they are prepared to issue the License).
New Licenses. (a) Identification. [***]
New Licenses. A new license will become effective on the date it is filed with the Human Resources Department. Only those licenses filed on or before May 1 or the date of Board action eliminating positions, whichever is earlier, may be used to exercise bumping rights. Only those licenses filed before a notice of recall is issued may be used for recall rights.
New Licenses. During the ALA term, upon ALA annual license fee payment, Customer will receive perpetual license rights for new licenses installed under the ALA equal in value to 30% of the ALA annual license fee. Pricing for such licenses shall be determined from the then current Novell Academic Price List.
New Licenses. Provided New Operator timely applied to IDPH and used best efforts to submit a correct and complete application, New Operator shall have received adequate assurance of obtaining the IDPH License, which may occur by receipt of a letter or email from IDPH stating that the License shall be issued upon notification of the Closing.
New Licenses. During the SLA term, upon payment of the annual School License Fees, Customer will receive perpetual license rights for new licenses declared under the SLA equal in value to 30% of the Annual Points Value as specified in the SLA Annual Fee Worksheet and for which the School License Fees have been paid. Details of such perpetual license rights (i.e. products and quantities) shall be determined by applying the 30% value against the number of points associated with such license as listed in the Novell Academic Price List that is current upon the date of termination. Upon termination of the SLA, Customer shall have the option to purchase additional perpetual license rights for all the new licenses installed under the SLA at that time, at the price listed in the then- current Novell Academic Price List.
New Licenses. With respect to all Merchandising Exploitation of Characters and Products (other than Merchandising of New Pictures, and Merchandising pursuant to Existing Merchandising Licenses):
New Licenses. [*] Elpida shall have executed and delivered the New Licenses. [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
New Licenses. Sanofi shall, and hereby does effective as of the effective date of termination, grant Denali (A) an exclusive, irrevocable license in the Terminated *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Area, with the right to grant multiple tiers of sublicenses, under Sanofi Know-How and Sanofi’s interest in any Joint Program Know-How, in each case, [***] (“Sanofi Unblocking Know-How”); and (B) an exclusive, irrevocable license in the Terminated Area, with the right to grant multiple tiers of sublicenses, under Sanofi Patents and Sanofi’s interest in any Joint Program Patent claiming or covering any Sanofi Unblocking Know-How [***] (collectively, the “Sanofi Unblocking Patent Rights”), in each case [***]. For clarity, the scope of the Sanofi Unblocking Know-How and Sanofi Unblocking Patent Rights subject to the foregoing license shall be determined based on [***], regardless of whether [***]. Further such license [***], except to the extent provided in Section 13.8.1(c)(ii) and [***]:
New Licenses. In the event that either Party believes that any new licenses under Third Party patents or other intellectual property rights covering Pleconaril, the Formulation, or the manufacture or use thereof (excluding any Product Improvement Licenses), are required for the manufacture, distribution, use and/or sale of Products containing Pleconaril or the Formulation by Schering or its Affiliates in the Field in the Territory (“New Licenses”) it shall promptly notify the other Party to that effect. As soon as possible following such notice, the Parties shall meet to agree on the need for such New Licenses and the appropriate scope of such New Licenses. If the Parties agree that any such New License is required to avoid liability for infringement of such Third Party patents or other intellectual property rights (other than any such infringement related to Product Improvements), then the Parties shall cooperate in the negotiation of such New License with Schering having primary responsible for the negotiation of such New Licenses. Schering shall keep ViroPharma fully informed during the negotiation of any New Licenses agreed to by the Parties, and shall reasonably consider any comments provided by ViroPharma regarding the terms and conditions of such New License. Except as provided in Section 6.10(c), Schering and its Affiliates shall not enter into any New License without ViroPharma’s prior written approval of the financial terms of such New License (such approval not to be unreasonably withheld). Schering and ViroPharma shall [***] responsibility for the payment of any licensee fee, milestone payments, royalties or other compensation due and owing to any Third Party in connection with any New Licenses agreed to by the Parties and approved by ViroPharma pursuant to this Section 6.10(b).
